Lineage Cell Therapeutics (LCTX) Total Non-Current Liabilities (2010 - 2026)

Lineage Cell Therapeutics' Total Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $22.7 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 19.04% year-over-year to $22.7 million in Q1 2026; TTM through Mar 2026 was $22.7 million, a 19.04% decrease from a year earlier, with the FY2025 full-year figure at $25.3 million, down 15.69% from the prior year.
• Total Non-Current Liabilities eased to $22.7 million in Q1 2026 per LCTX's latest filing, from $25.3 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $59.3 million in Q1 2022 and bottomed at $22.7 million in Q1 2026.
• The 5-year median for Total Non-Current Liabilities is $39.0 million (2023), against an average of $38.3 million.
• Across the five-year window, Total Non-Current Liabilities sank 38.14% in 2022 and declined 15.69% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $51.7 million in 2022, then declined by 24.61% to $39.0 million in 2023, then declined by 22.95% to $30.0 million in 2024, then retreated by 15.69% to $25.3 million in 2025, then retreated by 10.4% to $22.7 million in 2026.
• Per Business Quant, the three latest LCTX Total Non-Current Liabilities figures stand at $22.7 million (Q1 2026), $25.3 million (Q4 2025), and $23.7 million (Q3 2025).